Abstract
As the world grapples with the crisis of COVID-19, established economies and healthcare systems have been brought to their knees. Tough decisions regarding redirection of resources away from the management of conditions deemed "nonessential" are being made. How can we balance urgent resourcing of our acute crisis while not abandoning the real need of patients with osteoporosis? This article offers a few practical solutions.
Keywords:
Bisphosphonate; Bone mineral density; COVID-19; Denosumab; Fracture; Osteoporosis.
MeSH terms
-
Acute-Phase Reaction / chemically induced
-
Acute-Phase Reaction / diagnosis
-
Betacoronavirus*
-
Bone Density Conservation Agents / administration & dosage
-
Bone Density Conservation Agents / adverse effects
-
COVID-19
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / prevention & control*
-
Denosumab / administration & dosage
-
Diagnosis, Differential
-
Diphosphonates / adverse effects
-
Drug Administration Schedule
-
Health Care Rationing / organization & administration*
-
Humans
-
Osteoporosis / therapy*
-
Osteoporotic Fractures / etiology
-
Osteoporotic Fractures / prevention & control
-
Pandemics / prevention & control*
-
Patient Education as Topic
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / prevention & control*
-
Risk Assessment / methods
-
SARS-CoV-2
Substances
-
Bone Density Conservation Agents
-
Diphosphonates
-
Denosumab